Effect of Mepolizumab in OCS Dependent Severe Eosinophilic Asthma Patients with History of Omalizumab Treatment

被引：0
|
作者：
Prazma, Charlene M. [1 ]
Magnan, Antoine [2 ]
Price, Robert [3 ]
Ortega, Hector [1 ]
Yancey, Steven W. [1 ]
Albers, Frank C. [1 ]
机构：
[1] GlaxoSmithKline, Res Triangle Pk, NC USA
[2] Univ Nantes, Nantes, France
[3] GlaxoSmithKline, Stockley Pk, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2015年 / 135卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2014.12.1879
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L6
引用
收藏
页码：AB383 / AB383
页数：1
相关论文
共 50 条
  • [1] Effect Of Mepolizumab In Severe Eosinophilic Asthma Patients Eligible For Omalizumab Treatment
    Albers, F. C.
    Price, R.
    Yancey, S.
    Bradford, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [2] Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
    Magnan, A.
    Bourdin, A.
    Prazma, C. M.
    Albers, F. C.
    Price, R. G.
    Yancey, S. W.
    Ortega, H.
    ALLERGY, 2016, 71 (09) : 1335 - 1344
  • [3] Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
    Albers, Frank C.
    Hozawa, Soichiro
    Bratton, Daniel J.
    Yancey, Steven W.
    Prazma, Charlene M.
    Humbert, Marc
    Liu, Mark C.
    ALLERGY, 2020, 75 (04) : 942 - 946
  • [4] Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility
    Humbert, Marc
    Albers, Frank C.
    Bratton, Daniel J.
    Yancey, Steven W.
    Liu, Mark C.
    Hozawa, Soichiro
    Llanos, Jean-Pierre
    Kwon, Namhee
    RESPIRATORY MEDICINE, 2019, 154 : 69 - 75
  • [5] Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by exacerbations in previous year and maintenance use of OCS
    Liu, Mark
    Chipps, Bradley
    Munoz, Xavier
    Devouassoux, Gilles
    Bergna, Miguel
    Smith, Steven
    Albers, Frank
    Price, Robert
    Azmi, Jay
    Galkin, Dmitri
    Chapman, Kenneth
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB25 - AB25
  • [6] Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by prior omalizumab treatment duration
    Albers, Frank
    Liu, Mark C.
    Chipps, Bradley E.
    Chapman, Kenneth R.
    Munoz, Xavier
    Bergna, Miguel
    Devouassoux, Gilles
    Azmi, Jay
    Price, Robert
    Galkin, Dmitry
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB102 - AB102
  • [7] Effect of mepolizumab on exacerbation rate in patients with severe eosinophilic asthma by omalizumab eligibility and prior omalizumab use
    Humbert, M.
    Bratton, D. J.
    Yancey, S. W.
    Bradford, E. S.
    Liu, M. C.
    Hozawa, S.
    Albers, F. C.
    ALLERGY, 2018, 73 : 201 - 201
  • [8] Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma-Treatment effect by prior omalizumab treatment regimen
    Chapman, K. R.
    Galkin, D.
    Liu, M. C.
    Chipps, B.
    Munoz, X.
    Bergna, M.
    Devouassoux, G.
    Azmi, J.
    Mouneimne, D.
    Price, R.
    Albers, F. C.
    ALLERGY, 2018, 73 : 349 - 349
  • [9] Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
    Ortega, Hector G.
    Liu, Mark C.
    Pavord, Ian D.
    Brusselle, Guy G.
    FitzGerald, J. Mark
    Chetta, Alfredo
    Humbert, Marc
    Katz, Lynn E.
    Keene, Oliver N.
    Yancey, Steven W.
    Chanez, Pascal
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13): : 1198 - 1207
  • [10] Efficacy of mepolizumab in patients with severe eosinophilic asthma who had previously received omalizumab treatment
    Bradford, E. S.
    Nelsen, L. M.
    Bratton, D. J.
    Albers, F. C.
    Taille, C.
    Magnan, A.
    ALLERGY, 2017, 72 : 413 - 414
12345